Tuberculosis Research Units (P01 Clinical Trial Optional)
ID: 358995Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358995
Timeline
    Description

    The National Institutes of Health (NIH) is announcing a funding opportunity for the establishment of multidisciplinary Tuberculosis Research Units (TBRUs) through a grant program aimed at enhancing the understanding of Mycobacterium tuberculosis (Mtb) and its interactions with the host. This initiative seeks to foster collaborative research that characterizes the roles of bacterial and host heterogeneity in infection outcomes and disease progression, with a focus on identifying determinants relevant to Mtb establishment and dissemination. The total estimated program funding is $10 million, with approximately five awards expected, and interested applicants are encouraged to begin forming collaborations in anticipation of the Notice of Funding Opportunity (NOFO) expected to be published in September 2025. For further inquiries, potential applicants can contact Richard T. Robinson, Ph.D., at richard.robinson@nih.gov or by phone at 202-607-8565.

    Point(s) of Contact
    Richard T. Robinson, Ph.D. National Institute of Allergy and Infectious Diseases (NIAID)
    (202) 607-8565
    richard.robinson@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)." This initiative aims to solicit research applications focused on the preclinical development of lead candidate vaccines to combat Mycobacterium tuberculosis (Mtb) infection and disease, thereby enhancing the clinical pipeline of viable vaccine candidates. The program is critical for advancing public health efforts against tuberculosis, a significant global health challenge. The estimated total funding for this program is $4,730,000, with approximately five awards expected. Interested applicants can reach out to Katrin Eichelberg, MSc, PhD, at keichelberg@nih.gov or call 240-669-2921 for further information. Key deadlines include an estimated synopsis post date of September 8, 2025, and a close date of November 7, 2025, with awards anticipated to be made by July 1, 2026.
    Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment in both adults and children, particularly focusing on individuals with and without HIV. This initiative encourages innovative epidemiological and observational studies to better characterize post-TB lung disease (PTLD) and its associated health impacts, utilizing existing cohorts of TB participants. Interested applicants, including higher education institutions, non-profits, and government entities, must adhere to specific guidelines for submission through the NIH ASSIST system, with applications accepted until May 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)" aimed at supporting research into the immunometabolic changes induced by HIV that may elevate the risk of tuberculosis (TB) and hepatitis B virus (HBV) in individuals on combination antiretroviral therapy (cART). This initiative seeks to fund investigator-led studies that explore the long-term effects of HIV-related alterations in immune metabolism on disease progression and treatment responses, with a focus on identifying biomarkers and innovative therapies to mitigate these risks. The grant is open to a wide range of eligible applicants, including higher education institutions, non-profits, and for-profit organizations, with no cost-sharing requirements. Interested parties should note that the application submission deadlines range from April 2025 to January 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk," aimed at supporting research into the immunometabolic changes induced by HIV in individuals undergoing combination antiretroviral therapy. This initiative seeks to investigate how these alterations affect immune responses and increase the risk of subsequent infections, specifically tuberculosis (TB) and hepatitis B virus (HBV). The funding opportunity is particularly significant for advancing understanding in the field of HIV-related health risks and aims to foster innovative research approaches, including the use of machine learning and AI to identify biomarkers and therapeutic targets. Eligible applicants can receive up to $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-316.html.
    Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support," aimed at providing operational support for NBLs located at the University of Texas Medical Branch in Galveston, Texas, and Boston University in Massachusetts. The funding will support essential services such as facility maintenance, biosecurity, environmental health and safety compliance, and specialized research support, which are critical for conducting research on hazardous biological agents in alignment with NIAID's biodefense and emerging infectious diseases initiatives. With an estimated total program funding of $23 million and the expectation of awarding two grants, interested organizations are encouraged to prepare for application submission, with the anticipated synopsis posting on September 11, 2025, and a closing date of November 10, 2025. For further inquiries, potential applicants can contact Fayna Diaz San Segundo at fayna.diazsansegundo@nih.gov or by phone at 240-921-3931.
    Notice of Intent to Publish a Funding Opportunity Announcement for TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the TMD Collaborative for Improving Patient-Centered Translational Research (TMD IMPACT), aimed at advancing research on Temporomandibular Disorders (TMD). This initiative seeks to establish a national, interdisciplinary collaborative that will enhance TMD research, improve clinical care, and train future researchers in the field. The funding opportunity will provide a total of $7 million, with an award ceiling of $3.5 million for up to two cooperative agreements, and is expected to be published in Summer 2024, with applications due in Winter 2024. Interested applicants should prepare for the anticipated collaboration and project development in advance of the expected award date of July 1, 2025.
    Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed)," aimed at advancing research in mucosal immunology. This initiative seeks to establish a cooperative research group focused on understanding immune mechanisms and regulation at mucosal surfaces across various tracts, including respiratory, gastrointestinal, and urogenital systems. The program is significant for fostering innovative approaches and technologies to tackle complex questions in this field. The estimated total funding for this program is $3 million, with approximately five awards expected to be made. Interested applicants, particularly small businesses with relevant expertise, are encouraged to prepare for the application process, which will open following the publication of the Notice of Funding Opportunity (NOFO) expected on July 3, 2025. For further inquiries, potential applicants can contact Dr. Deborah L. Hodge at hodged@mail.nih.gov or by phone at 240-551-3037.
    Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing the upcoming Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional), aimed at supporting high-priority research topics in tobacco regulatory science. This program seeks to fund innovative research that will provide scientific data to inform the FDA's regulatory authorities concerning tobacco products, particularly in relation to the Family Smoking Prevention and Tobacco Control Act (FSPTCA). With an estimated total funding of $500,000 and the expectation of awarding four grants, the Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2025, with applications due in Winter 2026. For further inquiries, interested applicants can contact Erik Rodriquez, Ph.D., at TRSP@nih.gov or by phone at 301-827-2830.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.